LataMed AI Corp. (OTC: LMEDD) announced today that its 5-for-1 forward stock split has taken effect, marking a significant corporate milestone for the development-stage digital health company. The split, which was approved by FINRA and became effective at the opening of trading following the July 14, 2026, FINRA Daily List, increases the number of outstanding shares and is expected to improve market liquidity.
Under the terms of the split, the company's common stock now trades under the temporary symbol LMEDD, with the "D" designation indicating the corporate action. This temporary symbol is expected to remain for approximately 20 business days before reverting to LMED. The split also accompanies a mandatory share exchange and a new CUSIP number, 21116R404, replacing the prior CUSIP 21116R305.
Dr. Kevin Rodan Levy, CEO of LataMed AI Corp., emphasized the importance of this step: "Today's implementation of our forward stock split represents an important corporate milestone for LataMed AI. We appreciate the continued support of our shareholders and look forward to continuing the execution of our long-term strategy as we focus on expanding our telemedicine platform and pursuing commercialization opportunities for our CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms."
The company clarified that shareholders holding shares through brokerage accounts or in electronic book-entry form generally need not take any action, as brokerage firms and custodians are expected to process the corporate action automatically. For those holding physical stock certificates, surrender is not immediately required, but when certificates are presented for transfer, sale, or exchange, they will be processed under the new CUSIP and exchange procedures.
This forward split is part of LataMed AI's broader strategy to strengthen its capital structure and support its focus on AI-enabled healthcare solutions for emerging markets. The company's platforms, including CardioAI, PulmoAI, and NeuroAI, are designed to enhance telehealth infrastructure, patient engagement, and provider coordination. LataMed AI's initial regional focus is on Latin America, where it aims to address healthcare access challenges.
The announcement underscores the company's commitment to advancing its technology platforms and pursuing commercialization opportunities. For additional information, the company directs stakeholders to its website at https://latamed.ai and its SEC filings at www.sec.gov.
As a development-stage company, LataMed AI faces risks typical of emerging technology firms, including the need for financing, regulatory approvals, and successful deployment of its platforms. The forward stock split does not change the fundamental value of the company but is a tactical move to position the stock for future growth initiatives.
